These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Onset of optimal P2Y12-ADP receptor blockade after ticagrelor and prasugrel intake in Non-ST elevation acute coronary syndrome. Bonello L; Laine M; Camoin-Jau L; Noirot F; Guieu R; Dignat-George F; Paganelli F; Frere C Thromb Haemost; 2015 Oct; 114(4):702-7. PubMed ID: 26311415 [TBL] [Abstract][Full Text] [Related]
4. Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials. Galli M; Benenati S; Franchi F; Rollini F; Capodanno D; Biondi-Zoccai G; Vescovo GM; Cavallari LH; Bikdeli B; Ten Berg J; Mehran R; Gibson CM; Crea F; Pereira NL; Sibbing D; Angiolillo DJ Eur Heart J; 2022 Mar; 43(10):959-967. PubMed ID: 34918066 [TBL] [Abstract][Full Text] [Related]
5. Ticagrelor or prasugrel versus clopidogrel in elderly patients with an acute coronary syndrome: Optimization of antiplatelet treatment in patients 70 years and older--rationale and design of the POPular AGE study. Qaderdan K; Ishak M; Heestermans AA; de Vrey E; Jukema JW; Voskuil M; de Boer MJ; van't Hof AW; Groenemeijer BE; Vos GJ; Janssen PW; Bergmeijer TO; Kelder JC; Deneer VH; ten Berg JM Am Heart J; 2015 Nov; 170(5):981-985.e1. PubMed ID: 26542508 [TBL] [Abstract][Full Text] [Related]
6. De-escalation from Prasugrel or Ticagrelor to Clopidogrel in Patients with Acute Coronary Syndrome Managed with Percutaneous Coronary Intervention: An Updated Meta-analysis of Randomized Clinical Trials. Abdelazeem B; Shehata J; Abbas KS; El-Shahat NA; Baral N; Adhikari G; Khan H; Hassan M Am J Cardiovasc Drugs; 2022 May; 22(3):287-298. PubMed ID: 34651261 [TBL] [Abstract][Full Text] [Related]
13. Effect of Prehospital Crushed Prasugrel Tablets in Patients With ST-Segment-Elevation Myocardial Infarction Planned for Primary Percutaneous Coronary Intervention: The Randomized COMPARE CRUSH Trial. Vlachojannis GJ; Wilschut JM; Vogel RF; Lemmert ME; Delewi R; Diletti R; van der Waarden NWPL; Nuis RJ; Paradies V; Alexopoulos D; Zijlstra F; Montalescot G; Angiolillo DJ; Krucoff MW; Van Mieghem NM; Smits PC Circulation; 2020 Dec; 142(24):2316-2328. PubMed ID: 33315489 [TBL] [Abstract][Full Text] [Related]
14. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial. Gimbel M; Qaderdan K; Willemsen L; Hermanides R; Bergmeijer T; de Vrey E; Heestermans T; Tjon Joe Gin M; Waalewijn R; Hofma S; den Hartog F; Jukema W; von Birgelen C; Voskuil M; Kelder J; Deneer V; Ten Berg J Lancet; 2020 Apr; 395(10233):1374-1381. PubMed ID: 32334703 [TBL] [Abstract][Full Text] [Related]
15. Comparison of prasugrel and ticagrelor in patients with acute coronary syndrome undergoing percutaneous coronary intervention: A meta-analysis of randomized and non-randomized studies. Watti H; Dahal K; Zabher HG; Katikaneni P; Modi K; Abdulbaki A Int J Cardiol; 2017 Dec; 249():66-72. PubMed ID: 29121759 [TBL] [Abstract][Full Text] [Related]
16. Infarct Size Following Treatment With Second- Versus Third-Generation P2Y12 Antagonists in Patients With Multivessel Coronary Disease at ST-Segment Elevation Myocardial Infarction in the CvLPRIT Study. Khan JN; Greenwood JP; Nazir SA; Lai FY; Dalby M; Curzen N; Hetherington S; Kelly DJ; Blackman D; Peebles C; Wong J; Flather M; Swanton H; Gershlick AH; McCann GP J Am Heart Assoc; 2016 May; 5(6):. PubMed ID: 27247336 [TBL] [Abstract][Full Text] [Related]
17. Time-dependent benefits of pre-treatment with new oral P2Y Pepe M; Cafaro A; Paradies V; Signore N; Addabbo F; Bortone AS; Navarese EP; Contegiacomo G; Forleo C; Bartolomucci F; Di Cillo O; Bianchi FP; Zanna D; Favale S Catheter Cardiovasc Interv; 2019 Mar; 93(4):592-601. PubMed ID: 30269413 [TBL] [Abstract][Full Text] [Related]
18. Switching to Clopidogrel in Patients With Acute Coronary Syndrome Managed With Percutaneous Coronary Intervention Initially Treated With Prasugrel or Ticagrelor: Systematic Review and Meta-analysis. Hong J; Turgeon RD; Pearson GJ Ann Pharmacother; 2019 Oct; 53(10):997-1004. PubMed ID: 30999764 [No Abstract] [Full Text] [Related]
19. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Cuisset T; Deharo P; Quilici J; Johnson TW; Deffarges S; Bassez C; Bonnet G; Fourcade L; Mouret JP; Lambert M; Verdier V; Morange PE; Alessi MC; Bonnet JL Eur Heart J; 2017 Nov; 38(41):3070-3078. PubMed ID: 28510646 [TBL] [Abstract][Full Text] [Related]
20. Real-World Evidence on Disparities on the Initiation of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome. Yildirim M; Mueller-Hennessen M; Milles BR; Biener M; Hund H; Frey N; Giannitsis E; Salbach C J Am Heart Assoc; 2023 Aug; 12(16):e030879. PubMed ID: 37581388 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]